암 진단용 AI 시장 규모, 점유율, 동향 분석 보고서 : 컴포넌트별, 암 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

AI In Cancer Diagnostics Market Growth & Trends:

The global AI in cancer diagnostics market size is estimated to reach USD 996.12 million by 2030, registering to grow at a CAGR of 24.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing need for lowering healthcare costs, the rising importance of big data in healthcare, improving adoption of precision medicine, and declining hardware costs are key factors driving the growth.

The increasing scope of applications of artificial intelligence (AI) in various healthcare fields, including diagnostics; the rising prevalence of cancer; and the growing shortage of public health workforce are some of the key factors anticipated to fuel the adoption of artificial intelligence (AI) in cancer diagnostics over the forecast period. In addition, the increasing applicability of AI-based tools in cancer care and the rise in venture capital investments is further driving the surge in demand for this technology.

The presence of prominent players in the market such as Microsoft, Flatiron, Therapixel, and Tempus, is anticipated to positively impact the growth. These players are adopting strategies such as acquisitions, collaborations, expansions, and new product launches to increase the reach of their products in the industry and increase the availability of their products & services in diverse geographical areas. For instance, in December 2021, Microsoft announced a partnership with CVS Health to develop innovative solutions for patients to improve their health while empowering healthcare professionals with tools to better service patients.

Furthermore, the rising government support in the form of funding and initiatives for the development of healthcare infrastructure is anticipated to drive the demand for technologically advanced and cost-efficient devices over the forecast period.

AI In Cancer Diagnostics Market Report Highlights:

• Based on component, the software solutions segment dominated the market with a revenue share of 44.39% in 2024 and is expected to witness the fastest growth rate during the forecast period.
• Based on cancer type, breast cancer had a significant revenue share of 19.41% in 2024.
• Hospital segment dominated the market with the largest revenue share of 56.95% in 2024.
• North America AI in cancer diagnostics market dominated in 2023 with the largest share of 54.74%.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Component
  • 1.1.2. Cancer type
  • 1.1.3. End use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Component outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Artificial Intelligence In Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. Artificial Intelligence In Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. COVID-19 Impact
• 3.5. Case Study

Chapter 4. Artificial Intelligence In Cancer Diagnostics Market: Component Estimates & Trend Analysis

• 4.1. Component Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Artificial Intelligence In Cancer Diagnostics Market by Component Outlook
• 4.4. Software Solutions
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Hardware
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Artificial Intelligence In Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

• 5.1. Cancer Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Artificial Intelligence In Cancer Diagnostics Market by Cancer Type Outlook
• 5.4. Breast Cancer
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Lung Cancer
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Prostate Cancer
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.7. Colorectal Cancer
  • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.8. Brain Tumor
  • 5.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Artificial Intelligence In Cancer Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Artificial Intelligence In Cancer Diagnostics Market by End Use Outlook
• 6.4. Hospital
  • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.5. Surgical Centers and Medical Institutes
  • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Artificial Intelligence In Cancer Diagnostics Market: Regional Estimates & Trend Analysis, By Component, By Cancer Type, By End Use

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Innovators
• 8.4. Vendor Landscape
  • 8.4.1. EarlySign
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Technology Type benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cancer Center.ai
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Technology Type benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Microsoft
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Technology Type benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. FLATIRON HEALTH
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Technology Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. PathAI, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Technology Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Therapixel
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Technology Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Tempus AI, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Technology Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Paige AI Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Technology Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Kheiron Medical Technologies Limited
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Technology Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. SkinVision
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Technology Type benchmarking
    • 8.4.10.4. Strategic initiatives